In this context, we therefore aim to describe the early changes in the short term CGM-related metrics and additional relevant clinical measures in people with type 1 diabetes initiating insulin treatment with Omnipod 5 in a real-world setting. The gene discussed is INS; the disease is type 1 diabetes mellitus.